Crurated Announces Exclusive Availability of Vintage Collection Wines from Domaine Robert Groffier for Both Private Buyers and Restaurants Globally
LONDON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Crurated, the London-based membership wine community designed to connect connoisseurs with world-class producers, announces the availability of vintage collection wines from Domaine Robert Groffier. The collection will be sold exclusively to members of the Crurated community and will be available globally for private buyers and restaurants. The Groffier family are among the best winemakers in the Côte de Nuits. Originally founded by Robert Groffier’s father, Jules in the 1950s, the Domaine is now run by Robert’s grandson, Nicolas Groffier and his wife, Céline. For more information on membership and purchasing opportunities visit www.crurated.com.
Groffier and Crurated are also partnering to distribute the unique Groffier Collection as Magnums and beyond. The NFT technology from Crurated and gold capsule bottle toppers from Domaine Groffier offer the best insurance signifying authenticity for bottles directly from the Domaine.
The vintage collection on Crurated consists of the following lots:
- Vertical selection of Les Amoureuses (2016-2021) which is considered among the finest terroir in Côte de Nuits
- Horizontal selection from some of the finest terroirs in France from 2009
- Magnums and bottles from the Groffier private cellar representing every decade since 1970
- A fabulous Vertical of Chambertin Clos Magnum 1997-2008
The Gold Capsule on vintage bottles of wine signifies provenance.
This opportunity starts October 16, 2023, and these one-in-a-lifetime wines will be offered to Crurated members through private sale.
“Offering wines from our vintage collection through the use of NFTs and blockchain technology is a unique and very novel way to ensure provenance and that the wines are coming directly from the cellar where they have been aging since bottling,” said Nicolas. “We always try to find the best and most direct way to get our wines to consumers and restaurateurs and our partnership with Crurated delivers on this promise.”
“Nicolas takes quality very seriously and has taken it to an unprecedented level while focusing on innovation and also remaining loyal to the traditions passed down for generations,” said Alfonso de Gaetano, CEO & Founder of Crurated. “We continue to create exclusive partnerships with producers that further elevate the benefits we offer to our members. We are honored to have the chance to offer this collection and work with Nicolas and his team.”
Each bottle will be accompanied with an NFT. Recorded forever on the blockchain, the NFT will verify the authenticity of the bottle and provide other important details including provenance, ownership history, vintage, vineyard location, varietal, and other key details. The NFTs are easily accessible by tapping on an NFC or RFID enabled phone. The bottle history is also updated via a new blockchain recording anytime the wine is resold and the token moves from one client to another.
Founded in 2021, Crurated is the first blockchain-based, online wine community that certifies the provenance of every bottle it sells with an NFT. The team is passionate about curating opportunities for members to purchase rare wines directly from the domaine where they were produced. Labels including Charles Lachaux, Domaine Arnoux-Lachaux, and Robert Groffier have signed exclusive distribution deals with Crurated with more to come. Members can also interact with partner winemakers at private events, along with celebrated chefs, in stunning locations all over the globe. In the future, Crurated will be expanding its product offering into other luxury segments and metaverse-driven technology. For more information visit www.crurated.com.
Photos accompanying this announcement are available at
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Managers’ transactions9.12.2023 18:12:40 CET | Press release
December 9, 2023 Announcement no. 21 Managers’ transactions COPENHAGEN, DENMARK and BOSTON, MA, December 9, 2023, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), has received notice pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transaction related to shares in BioPorto made by persons discharging managerial responsibilities in BioPorto and/or persons closely related with them. 1. Details of the person discharging managerial responsibilities/person closely associated a) Name Singer Asefzadeh Family Holding Trust 2. Reason for the notification a) Position/status Closely associated person to Michael S. Singer, member of the Board of Directors of BioPorto A/S b) Initial notification/amendment Initial notification 3. Details of the issuer a) Name BioPorto A/S b) LEI 5299004SWFL5JAN4W830 4. Details of the transaction(s) a) Description of the financial instrument type of instrument and Identification code Shares, ISIN code DK0011048619 b) Nature o
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)9.12.2023 18:00:00 CET | Press release
Media Release COPENHAGEN, Denmark; December 9, 2023 Data from the pivotal phase 1/2 EPCORE™ NHL-1 study showed 82 percent overall response rate (ORR), 63 percent complete response (CR) and 67 percent minimal residual disease (MRD) negativity in patients with relapsed/refractory (R/R) follicular lymphoma (FL) treated with subcutaneous epcoritamab Results presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition include data from an optimized step-up dosing schedule for FL patients showing meaningful reduction in risk and severity of cytokine release syndrome (CRS) Follicular lymphoma is the second most common form of non-Hodgkin’s lymphoma, is considered incurable and can be difficult to treat in the R/R setting Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) todayannounced new data from the ongoing phase 1/2 EPCORE™ NHL-1 clinical trial investigating epcoritamab (DuoBody® CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, demo
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG51019.12.2023 18:00:00 CET | Press release
Additional safety and efficacy data further support potential of innovative, decentralized approach to CAR-T manufacturing and transformational impact on patients with severe hematologic cancersTwo poster presentations include recent data updates and additional data not included in the ASH abstracts Galapagos to host a Key Opinion Leader (KOL) event with live webcast on Sunday, 10 December 2023 at 11:00 am PT/20:00 CET Mechelen, Belgium; 9 December 2023, 18:00 CET; Galapagos NV (Euronext & NASDAQ: GLPG) topresent additional encouraging clinical data from the ongoing Phase 1/2 CD19 CAR-T studies, EUPLAGIA-1 with GLPG5201 and ATALANTA-1 with GLPG5101, in patients with relapsed/refractory chronic lymphocytic leukemia (rrCLL), with or without Richter transformation, and non-Hodgkin lymphoma (rrNHL), during two poster sessions at the 65th American Society of Hematology (ASH) Annual Meeting taking place in San Diego, from 9-12 December. “We are very pleased to share promising new data from o
New data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A9.12.2023 17:30:00 CET | Press release
Phase III HAVEN 7 primary data presented at ASH 2023 provide additional confidence in the favourable efficacy and safety profile of subcutaneous Hemlibra given soon after birth 1At nearly two years median follow-up in the descriptive, single-arm study, no babies experienced spontaneous bleeds requiring treatment, and all treated bleeds were as a result of trauma 1Safety results were consistent with previous studies of Hemlibra, with no new safety signals observed 1The HAVEN 7 study was developed in collaboration with the haemophilia A community, to generate additional evidence for the prophylactic treatment of infants with haemophilia A Basel, 09 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the primary analysis of the Phase III HAVEN 7 study reinforced the efficacy and safety of Hemlibra® (emicizumab) in previously untreated or minimally treated infants with severe haemophilia A without factor VIII inhibitors. Results showed that Hemlibra achieved meaningful
Bulletin from Annual General Meeting in SkiStar AB9.12.2023 16:00:00 CET | Press release
At SkiStar AB (publ)’s annual general meeting, held in Sälen on 9 December 2023, the following decisions were made. A dividend of SEK 2.60 per share was adopted. Record day 12 December 2023.Lena Apler, Fredrik Paulsson, Gunilla Rudebjer, Anders Sundström, Anders Svensson and Vegard Søraunet were re-elected to the board and Carina Åkerström was elected as new board member.Anders Sundström was re-elected chairman of the board.Board fees, including committee fees, were raised to a total of SEK 2,890,000 (2022: SEK 2,810,000). The fees shall be distributed as follows: SEK 670,000 (650,000) to the chairman of the board and SEK 310,000 (300,000) each to the other non-executive directors. Audit committee members will receive total fees of SEK 240,000 (unchanged), distributed as follows: SEK 120,000 to the committee chairman and SEK 60,000 to each of the other two members. Remuneration committee members will receive total fees of SEK 120,000 (unchanged), distributed as follows: SEK 60,000 to t